{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+-+saline&page=41",
    "query": {
      "intervention": "Placebo - saline",
      "page": 41
    },
    "page_size": 10
  },
  "pagination": {
    "page": 41,
    "page_size": 10,
    "total_count": 3542,
    "total_pages": 355,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+-+saline&page=42&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+-+saline&page=40&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T17:29:15.745Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07079761",
      "title": "Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post Traumatic Stress Disorder"
      ],
      "interventions": [
        {
          "name": "Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer.",
          "type": "DRUG"
        },
        {
          "name": "Matching IV Placebo",
          "type": "OTHER"
        },
        {
          "name": "Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 96,
      "start_date": "2025-08-04",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-05",
      "last_synced_at": "2026-11-19T17:29:15.745Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07079761"
    },
    {
      "nct_id": "NCT05074485",
      "title": "Discovery and Analytical Validation of Inflammatory Bio-signatures of the Human Pain Experience",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "anakinra",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Nociceptive pain challenge",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alan Prossin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 70,
      "start_date": "2021-07-19",
      "completion_date": "2026-05-07",
      "has_results": false,
      "last_update_posted_date": "2023-12-05",
      "last_synced_at": "2026-11-19T17:29:15.745Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05074485"
    },
    {
      "nct_id": "NCT00333515",
      "title": "Pharmacokinetic (PK) and Safety Study of Plasma-derived Human Butyrylcholinesterase Administered Intravenously",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Chemical Terrorism",
        "Chemical Warfare"
      ],
      "interventions": [
        {
          "name": "Human Butyrylcholinesterase (HuBChE) derived from human plasma",
          "type": "DRUG"
        },
        {
          "name": "Placebo: Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 28,
      "start_date": "2007-01-01",
      "completion_date": "2008-08-01",
      "has_results": false,
      "last_update_posted_date": "2021-05-05",
      "last_synced_at": "2026-11-19T17:29:15.745Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00333515"
    },
    {
      "nct_id": "NCT00534313",
      "title": "Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriatic Arthritis"
      ],
      "interventions": [
        {
          "name": "Abatacept",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 191,
      "start_date": "2007-11",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2012-08-01",
      "last_synced_at": "2026-11-19T17:29:15.745Z",
      "location_count": 19,
      "location_summary": "Huntsville, Alabama • Palm Desert, California • Palo Alto, California + 16 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Bridgeport",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00534313"
    },
    {
      "nct_id": "NCT03392389",
      "title": "Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Metapneumovirus and Human Parainfluenza Infection"
      ],
      "interventions": [
        {
          "name": "mRNA-1653",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 124,
      "start_date": "2017-12-04",
      "completion_date": "2019-07-29",
      "has_results": false,
      "last_update_posted_date": "2020-02-06",
      "last_synced_at": "2026-11-19T17:29:15.745Z",
      "location_count": 3,
      "location_summary": "Omaha, Nebraska • Austin, Texas • Fort Worth, Texas",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03392389"
    },
    {
      "nct_id": "NCT02465268",
      "title": "Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Glioblastoma",
        "Malignant Glioma",
        "Astrocytoma, Grade IV",
        "GBM"
      ],
      "interventions": [
        {
          "name": "pp65-shLAMP DC with GM-CSF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "unpulsed PBMC and saline",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Td",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        },
        {
          "name": "pp65-flLAMP DC with GM-CSF",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 175,
      "start_date": "2016-08-09",
      "completion_date": "2023-11-30",
      "has_results": true,
      "last_update_posted_date": "2025-01-14",
      "last_synced_at": "2026-11-19T17:29:15.745Z",
      "location_count": 3,
      "location_summary": "Gainesville, Florida • Orlando, Florida • Durham, North Carolina",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02465268"
    },
    {
      "nct_id": "NCT05199818",
      "title": "Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chemotherapy-induced Nausea and Vomiting"
      ],
      "interventions": [
        {
          "name": "Palonosetron HCl Buccal Film 0.5 mg",
          "type": "DRUG"
        },
        {
          "name": "IV Palonosetron 0.25 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xiamen LP Pharmaceutical Co., Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 328,
      "start_date": "2022-03-01",
      "completion_date": "2023-11",
      "has_results": false,
      "last_update_posted_date": "2023-01-20",
      "last_synced_at": "2026-11-19T17:29:15.745Z",
      "location_count": 13,
      "location_summary": "Chandler, Arizona • Anaheim, California • Lakeland, Florida + 9 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05199818"
    },
    {
      "nct_id": "NCT06236113",
      "title": "Low Dose Ketamine for Blunt Thoracic Trauma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Blunt Injury of Thorax",
        "Multiple Rib Fractures, Involving Three Ribs"
      ],
      "interventions": [
        {
          "name": "Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "North Memorial Health Care",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2021-10-01",
      "completion_date": "2023-06-26",
      "has_results": true,
      "last_update_posted_date": "2024-05-21",
      "last_synced_at": "2026-11-19T17:29:15.745Z",
      "location_count": 1,
      "location_summary": "Robbinsdale, Minnesota",
      "locations": [
        {
          "city": "Robbinsdale",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06236113"
    },
    {
      "nct_id": "NCT01691508",
      "title": "Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Mepolizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "OCS (prednisone/prednisolone)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 135,
      "start_date": "2012-10",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2017-03-23",
      "last_synced_at": "2026-11-19T17:29:15.745Z",
      "location_count": 8,
      "location_summary": "Long Beach, California • Denver, Colorado • New Haven, Connecticut + 5 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01691508"
    },
    {
      "nct_id": "NCT07803250",
      "title": "Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rotator Cuff Tear"
      ],
      "interventions": [
        {
          "name": "BPC-157",
          "type": "DRUG"
        },
        {
          "name": "Sham (No Treatment)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Arkansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2027-01-01",
      "completion_date": "2027-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-11-19T17:29:15.745Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07803250"
    }
  ]
}